DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)

Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Respiratory Disorders

Intervention: Salmeterol and Fluticasone (Drug)

Phase: N/A

Status: Completed

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline

Summary

The purpose of this post-marketing surveillance is to detect adverse drug reactions (particularly clinically significant adverse drug reactions) occurring in clinical settings, to examine factors likely to affect the safety and efficacy in the Japanese asthma patients treated with fluticasone propionate and salmeterol xinafoate.

Clinical Details

Official title: Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)

Study design: Time Perspective: Prospective

Primary outcome: The number of incidence of adverse events in Japanese asthma patients treated with fluticasone propionate and salmeterol xinafoate

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Must use fluticasone and salmeterol for the first time

Exclusion Criteria:

- Patients with hypersensitivity to salmeterol and fluticasone

- Patients with infection which salmeterol and fluticasone is not effective

- Patients with deep mycosis

Locations and Contacts

Additional Information

Starting date: October 2007
Last updated: July 14, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017